For adults with mild to moderate COVID-19, early management of simnotrelvir plus ritonavir reduces the time to sustained resolution of symptoms, according to an article published in the Jan. 18 issue of the New England Journal of Medicine.
Bin Cao, M. D. , of the Institute of Respiratory Medicine of the Chinese Academy of Medical Sciences in Beijing, and colleagues recruited 1208 patients at 35 sites in China with mild to moderate COVID-19 and symptom onset in the past 3 days to obtain 750 mg. of simnotrelvir plus one hundred mg of ritonavir or placebo twice for five days (603 and 605 patients, respectively).
The researchers found that the time to sustained resolution of COVID-19 symptoms was particularly shorter in the simnotrelvir group than in the placebo group (180. 1 vs. 216. 0 hours) among patients in the modified intention-to-treat population. from baseline higher in the simnotrelvir group than in the placebo group on day five (mean difference, −1. 51 ± 0. 14 log10 copies/mL). A higher incidence of treatment-emergent adverse events was observed in the simnotrelvir group compared to the placebo group. organization (29. 0 percent vs. 21. 6 percent); Most adverse occasions were mild or moderate.
“Early administration of simnotrelvir plus ritonavir was effective in shortening the time to symptom resolution among adult patients with COVID-19, without evident safety concerns,” the authors write.
The study was funded by Jiangsu Simcere Pharmaceutical Co. , the maker of simnotrelvir.
Please choose the appropriate maximum category to facilitate the processing of your request
Thank you for taking the time to provide feedback to editors.
Your opinion is for us. However, we do not guarantee individual replies due to the high volume of messages.